AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06262607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical vehicle gel administered once daily
Study NCT04850027 — intervention group
Intervention type: PROCEDURE
Intervention: TME+Lateral lymph node dissection.
Description: TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
Study NCT05641467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
Study NCT05540171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral health education and instructions/training for self-oral care
Description: Education intervention
Study NCT05653362 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Coconut Oil
Description: Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
Study NCT05653362 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Commercial Ultrasound Gel
Description: Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
Study NCT05414695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real acupuncture
Description: Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
Study NCT05414695 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
Study NCT06323889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Alternate Day Fasting
Description: Participants are instructed to fast every other day.
Study NCT06323889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-Restricted Eating
Description: Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day
Study NCT06323889 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight-loss counseling
Description: Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
Study NCT06615167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALZGUARD
Description: A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.
Study NCT06615622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo
Description: Thiotacid 300 mg tab once/day
Study NCT06571552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Plasma Exchange followed by Double Filtration Plasmapheresis
Description: Double Filtration Plasmapheresis followed by Single Plasma Exchange
Study NCT06045286 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: High- and Low-dose radiotherapy
Description: High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
Study NCT06045286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
Study NCT06005142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eriomin
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 426c.Mod.Core-C4b
Description: self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
Study NCT06005142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eriomin
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
Study NCT06005142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Washout
Description: After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
Study NCT06005142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Washout
Description: After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
Study NCT06005142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3M-052-AF
Description: 3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension (Alum)
Description: Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum hydroxide suspension (Alum)
Description: Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.
Study NCT06613789 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Diluent
Description: Tris-NaCl buffer.
Study NCT06615128 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sample to detect sCD25 from systemic sclerosis and Healthy control.
Study NCT06005142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
Study NCT06521658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of retroflexion
Description: The intervention is the timing of the retroflexion/looping of the colonoscope in the rectum
Study NCT05610774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
Study NCT05610774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
Study NCT05802173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795, 0.0025%
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study NCT05802173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795, 0.02%
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study NCT05802173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDM-105795 topical vehicle solution
Description: The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study NCT06434649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrafascial robotic assisted radical prostatectomy via posterior approach
Description: Extrafascial robotic assisted radical prostatectomy via posterior approach will be applied in the intermediate or high risk patients.
Study NCT06434649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extrafascial robotic assisted radical prostatectomy via anterior approach
Description: Extrafascial robotic assisted radical prostatectomy via anterior approach will be applied in the intermediate or high risk patients.
Study NCT06614075 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire and anthropometric measurement
Description: Questionnaire including sociodemographic characteristics, lifestyle habits, body weight, height, dietary assessment and diabetes risk; Anthropometric measurement including waist circumference
Study NCT06685276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 5mg qd, po, 2 weeks on/1 week off, q3w, or 3mg qd, po, q3w.
Study NCT06685276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg, iv, d1, q3w.
Study NCT06685276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide: 30mg/m2, po, biw.
Study NCT06684743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV prefusion F protein-based vaccine
Description: For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
Study NCT06692556 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant radiotherapy
Description: Patients will receive an adjuvant radiotherapy corresponding to an equivalent dose of 45 to 50 Gy (Equivalent Dose in 2 Gy Fractions \[EQD2\] with a tumor alpha/beta ratio of 10 Gy) delivered on the operating bed.~Patients will be treated by :~* either external radiation therapy using high-energy electrons or photons:~  * 45 Gy in 15 fractions of 3 Gy~ * 50 Gy in 25 fractions of 2 Gy~* or interstitial brachytherapy or brachytherapy via skin applicators:~  * 36 Gy in 8 fractions of 4.5 Gy~ * 36 Gy in 9 fractions of 4 Gy~ * 40 Gy in 8 fractions of 5 Gy~Radiation therapy should be started within 8 weeks after surgery (or 10 if delayed healing).~Patients will be monitored regularly until the date of the first relapse (local, regional or metastatic), or until the date of death (if no relapse).~Regardless of the type of relapse, remedial treatments will be left to the the investigator's discretion up to the first metastatic relapse.
Study NCT06693882 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EYETRONIC Nextwave System
Description: Eyetronic Nextwave is a neurostimulation device that stimulates the optic nerve non-invasively using transcranial alternating current stimulation delivered through goggles in patients presenting with glaucoma.~Eyetronic is approved in Europe for the treatment of glaucoma to possibly delay progression of visual field (VF) loss for at least 12 months. The indication for use in Europe includes all patients suffering from neuropathies of the optic nerve resulting in loss of VF. Two studies conducted in Europe have demonstrated improvement in visual fields following 10-days of optic nerve stimulation treatment with this device. In the current study, the Eyetronic system will be used to treat only those individuals who have visual field loss from glaucoma.
Study NCT05416749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8MW2311
Description: All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
Study NCT05283928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoDensification (OD) protocol
Description: Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.
Study NCT05283928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard drilling (SD) protocol (NobelReplace® Conical)
Description: osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
Study NCT06272669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
Study NCT05616026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
Study NCT06272669 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
Study NCT06272669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-tDCS
Description: For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
Study NCT06163937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT06163937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT06163937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed fruit juice
Description: Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT06394492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: SHR-A1921 dose 1
Study NCT06394492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin dose 2
Study NCT06394492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel dose 3
Study NCT06394492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan dose 4
Study NCT06358963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive 30 mg of Coq10
Description: Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Study NCT06358963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Medicare Drugs
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Study NCT06358963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Medicare Drugs
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Study NCT05645315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection and TQB2450 injection
Description: TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
Study NCT06395688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one
Description: AEF0117 soft capsules of 1mg
Study NCT06395688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo soft capsules (identical to active compound)
Study NCT06395688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soft capsules (identical to active compound)
Study NCT05662397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST-1011
Description: HST-1011 given orally
Study NCT05662397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
Study NCT05760612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and nelatinib
Description: Postoperative adjuvant treatment, for about 1 year
Study NCT05760612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab and Parstuzumab
Description: Postoperative adjuvant treatment, for about 1 year
Study NCT06574165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training
Description: 6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking. Each center-based session will include 45 minutes of aerobic exercise in addition to balance and flexibility exercises to promote cool-down. During each exercise session, they will also be asked to wear a heart rate monitor to measure mean pulse during their exercise sessions.
Study NCT06569251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg QD
Description: Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
Study NCT06569251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 6 mg BID
Description: Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
Study NCT04564495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated exercise
Description: Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.